Opinion on General Business in North America

Published within

« | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | ... | » »|

Type Product title / description Pub Price
CommentWire
CommentWire

Alkermes/Janssen: no FDA respite for Risperdal

Janssen's substantial slice of the lucrative antipsychotics market is under threat, even though the FDA may eventually approve injectable Risperdal if its makers provide more evidence of its safety. The agency has already approved an extended release formulation of Pfizer's Geodon, and this drug will now enjoy substantial first-to-market advantage.

Published By Datamonitor
04 Jul 2002
Expert View
Expert View

All out for OTC

Published By Datamonitor
02 Sep 2001
CommentWire
CommentWire

Allergan: new Botox indication nothing to frown at

Allergan is seeking approval for its drug Botox in stroke-related spasticity. The patient potential for this indication is 1.8 million in the US alone, and there is no significant competition - so it will greatly boost Botox's annual revenues. Despite the drug's reputation as an anti-wrinkle therapy, Botox is also useful in several non-cosmetic indications.

Published By Datamonitor
10 Oct 2002
CommentWire
CommentWire

Alliance OneSource: teaming up pays off in Cleveland

Published By Datamonitor
10 Sep 2001
CommentWire
CommentWire

Allianz: trying to build an alliance

Published By Datamonitor
26 Mar 2001
CommentWire
CommentWire

Allstate: capitalizing on convergence

Published By Datamonitor
30 Jul 2001
CommentWire
CommentWire

Alpharma: fight for blockbuster gabapentin heats up

Alpharma has received market exclusivity for the anticonvulsant gabapentin, which is currently protected under patent by Pfizer, using the brand name Neurontin. Alpharma is expected to wait for a court ruling on the validity of Pfizer's production patent before entering the market. That should allow time for Pfizer to launch its follow on product, pregabalin, thus protecting future revenues.

Published By Datamonitor
03 Feb 2003
CommentWire
CommentWire

AltaVista: the view doesn't look high at all

Published By Datamonitor
12 Jan 2001
CommentWire
CommentWire

Alteon: ALT-711 could generate $1.3 billion by 2010

Although the results of a US study show ISH continues to be under treated, this represents an opportunity for Alteon, which is developing ALT-711 specifically for ISH. Providing awareness of ISH is increased, Datamonitor forecasts that ALT-711 could generate sales of $1.3 billion by 2010, just three years after launch.<BR />

Published By Datamonitor
28 Mar 2003
CommentWire
CommentWire

Alteon: new trial for promising 'multi-modal' drug

Alteon's developmental drug ALT-711 looks promising for a broad range of age-related cardiovascular conditions. Its greatest advantage of the compound is that it is 'multi-modal' in action, potentially treating the underlying cause of several conditions in a single drug. If Alteon can find a strong marketing partner, the drug could prove highly successful.

Published By Datamonitor
17 Jul 2002

« | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | ... | » »|

No help is available.